scholarly journals Targeting neutrophils using novel drug delivery systems in chronic respiratory diseases

2020 ◽  
Vol 81 (4) ◽  
pp. 419-436 ◽  
Author(s):  
Dinesh K. Chellappan ◽  
Lim W. Yee ◽  
Kong Y. Xuan ◽  
Kishen Kunalan ◽  
Lim C. Rou ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Respiratory Diseases ◽  
Delivery Systems ◽  
Chronic Respiratory Diseases ◽  
Novel Drug

scholarly journals Increasing complexity and interactions of oxidative stress in chronic respiratory diseases: An emerging need for novel drug delivery systems

2019 ◽  
Vol 299 ◽  
pp. 168-178 ◽  
Author(s):  
Kamal Dua ◽  
Vamshikrishna Malyla ◽  
Gautam Singhvi ◽  
Ridhima Wadhwa ◽  
Rapalli Vamshi Krishna ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Respiratory Diseases ◽  
Delivery Systems ◽  
Chronic Respiratory Diseases ◽  
Novel Drug

scholarly journals Interactions between microbiome and lungs: Paving new paths for microbiome based bio-engineered drug delivery systems in chronic respiratory diseases

2019 ◽  
Vol 310 ◽  
pp. 108732 ◽  
Author(s):  
Dinesh Kumar Chellappan ◽  
Quinnie Ling Sze Ning ◽  
Sandra Khoo Su Min ◽  
Saw Yan Bin ◽  
Pang Jia Chern ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Respiratory Diseases ◽  
Delivery Systems ◽  
Chronic Respiratory Diseases

scholarly journals Interactions with the macrophages: An emerging targeted approach using novel drug delivery systems in respiratory diseases

2019 ◽  
Vol 304 ◽  
pp. 10-19 ◽  
Author(s):  
Meenu Mehta ◽  
Deeksha ◽  
Neha Sharma ◽  
Manish Vyas ◽  
Navneet Khurana ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Respiratory Diseases ◽  
Delivery Systems ◽  
Novel Drug ◽  
Targeted Approach

scholarly journals Advancing of Cellular Signaling Pathways in Respiratory Diseases Using Nanocarrier Based Drug Delivery Systems

2020 ◽  
Vol 26 (42) ◽  
pp. 5380-5392 ◽  
Author(s):  
Meenu Mehta ◽  
Daljeet Singh Dhanjal ◽  
Saurabh Satija ◽  
Ridhima Wadhwa ◽  
Keshav Raj Paudel ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cell Signaling ◽  
Signaling Pathways ◽  
Drug Delivery Systems ◽  
Respiratory Diseases ◽  
Cellular Signaling ◽  
Delivery Systems ◽  
Chronic Respiratory Diseases ◽  
Lung Cancer Patients ◽  
Cell Signaling Pathways

Cell Signaling pathways form an integral part of our existence that allows the cells to comprehend a stimulus and respond back. Such reactions to external cues from the environment are required and are essential to regulate the normal functioning of our body. Abnormalities in the system arise when there are errors developed in these signals, resulting in a complication or a disease. Presently, respiratory diseases contribute to being the third leading cause of morbidity worldwide. According to the current statistics, over 339 million people are asthmatic, 65 million are suffering from COPD, 2.3 million are lung cancer patients and 10 million are tuberculosis patients. This toll of statistics with chronic respiratory diseases leaves a heavy burden on society and the nation's annual health expenditure. Hence, a better understanding of the processes governing these cellular pathways will enable us to treat and manage these deadly respiratory diseases effectively. Moreover, it is important to comprehend the synergy and interplay of the cellular signaling pathways in respiratory diseases, which will enable us to explore and develop suitable strategies for targeted drug delivery. This review, in particular, focuses on the major respiratory diseases and further provides an in-depth discussion on the various cell signaling pathways that are involved in the pathophysiology of respiratory diseases. Moreover, the review also analyses the defining concepts about advanced nano-drug delivery systems involving various nanocarriers and propose newer prospects to minimize the current challenges faced by researchers and formulation scientists.

Novel Nano Carriers for the Treatment of Progressive Auto Immune Disease Rheumatoid Arthritis

2020 ◽  
Vol 26 ◽  
Author(s):  
Ritu Mishra ◽  
Swati Gupta
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Delivery ◽  
Autoimmune Disease ◽  
Drug Delivery Systems ◽  
Clinical Manifestations ◽  
Adaptive Immune Response ◽  
Delivery Systems ◽  
Current Therapy ◽  
Genetic And Environmental Factors ◽  
Novel Drug

Background: Rheumatoid arthritis (RA) is the most common occurring progressive, autoimmune disease, affecting 1% of the population and the ratio of affected women is three times as compared to men in most developing countries. Clinical manifestations of RA are the presence of anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF) in blood, tendered joints and soreness of the muscles. Some other factors which may lead to chronic inflammation are genetic and environmental factors as well as adaptive immune response. Several conventional drugs are available for the treatment of RA but have their own drawbacks which can be overcome by the use of novel drug delivery systems. : The objective of the present review is to focus on the molecular pathogenesis of the disease and its current conventional treatment with special reference to the role of novel drug delivery systems encapsulating anti rheumatic drugs and herbal drugs in passive and receptor mediated active targeting against RA. On reviewing the conventional and current therapeutics agains RA, we conclude that, although the current therapy for the treatment of RA is capable enough, yet more advances in the field of targeted drug delivery will sanguinely result in effective and appropriate treatment of this autoimmune disease.

Provesicles as Novel Drug Delivery Systems

2015 ◽  
Vol 16 (4) ◽  
pp. 344-364 ◽  
Author(s):  
Zerrin Bayindir ◽  
Nilufer Yuksel
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Novel Drug

Current Perspectives on Novel Drug Delivery Systems and Therapies for Management of Prostate Cancer: An Inclusive Review

2017 ◽  
Vol 18 (11) ◽  
Author(s):  
Rohit R. Bhosale ◽  
H. V. Gangadharappa ◽  
Umme Hani ◽  
Riyaz Ali M. Osmani ◽  
Rudra Vaghela ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Novel Drug

Role of novel drug delivery systems in coronavirus disease-2019 (covid-19): time to act now

2020 ◽  
Vol 17 ◽  
Author(s):  
Neeraj Mittal ◽  
Varun Garg ◽  
Sanjay Kumar Bhadada ◽  
O. P. Katare
Keyword(s):  
Drug Delivery ◽  
Targeted Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
World Health ◽  
Ongoing Research ◽  
Standard Drug ◽  
Corona Virus ◽  
Novel Drug

: The corona virus disease 2019 (COVID-19) has found its roots from Wuhan (China). COVID-19 is caused by a novel corona virus SARS-CoV2, previously named as 2019-nCoV. COVID-19 has spread across the globe and declared as pandemic by World health organization (WHO) on 11th March, 2020. Currently, there is no standard drug or vaccine available for the treatment, so repurposing of existing drugs is the only solution. Novel drug delivery systems (NDDS) will be boon for the repurposing of drugs. The role of various NDDS in repurposing of existing drugs for treatment of various viral diseases and their relevance in COVID-19 has discussed in this paper. It focuses on the currently ongoing research in the implementation of NDDS in COVID-19. Moreover it describes the role of NDDS in vaccine development for COVID-19. This paper also emphasizes how NDDS will help to develop the improved delivery systems (dosage forms) of existing therapeutic agents and also explore the new insights to find out the void spaces for a potential targeted delivery. So in these tough times, NDDS and nanotechnology can be a safeguard to humanity.

Sign in / Sign up

Export Citation Format

Share Document